Nomegestrol Acetate: The Complete HRT Guide

Quick Reference Card

Overview / What Is Nomegestrol Acetate?

The Basics

Nomegestrol acetate, often referred to by its abbreviation NOMAC, is a progestogen medication used in menopausal hormone therapy and for the treatment of various gynecological conditions. If you are taking estrogen therapy and still have your uterus, you need a progestogen to protect your uterine lining from the overgrowth that estrogen alone can cause. NOMAC is one option for providing that protection.

What sets NOMAC apart from many other progestogens is its chemical lineage. While older progestins like norethindrone and levonorgestrel are derived from testosterone (which is why they sometimes carry androgenic side effects like acne and changes in cholesterol), NOMAC belongs to the 19-norprogesterone family. It was designed specifically to be close to natural progesterone in its selectivity, binding strongly to the progesterone receptor while having essentially no interaction with estrogen, glucocorticoid, or mineralocorticoid receptors [1]. This selectivity translates into a side effect profile that many clinicians consider favorable, particularly regarding metabolic neutrality.

NOMAC has been used in clinical practice since its introduction in Europe in 1986, initially marketed as Lutenyl for gynecological disorders and menopausal symptom management. It is widely prescribed in France, Italy, Belgium, and several other European countries, as well as in parts of Latin America and Asia. One important caveat for readers in North America: NOMAC is not approved by the FDA or Health Canada and is not available in the United States or Canada [2].

In the HRT context, NOMAC is most commonly prescribed as part of the Naemis combination (1.5 mg estradiol + 3.75 mg NOMAC) in a cyclic sequential regimen. It is also available as a standalone tablet (Lutenyl, 3.75 mg or 5 mg) for use alongside separately prescribed estrogen or for gynecological conditions without estrogen.

The Science

Nomegestrol acetate (17alpha-acetoxy-6-methyl-19-norpregna-4,6-diene-3,20-dione; C23H30O4; molecular weight 370.489 g/mol) is a synthetic norpregnane steroid classified as a 19-norprogesterone derivative. It was first described in the literature in 1983 under the developmental code name TX-066 and was developed by Theramex Laboratories in Monaco [1][2].

NOMAC occupies a distinct position in progestogen pharmacology. The 19-norprogesterone structural backbone differentiates it from the 19-nortestosterone derivatives (norethindrone, levonorgestrel, desogestrel) that dominated earlier hormonal therapy. This structural distinction has functional consequences: NOMAC demonstrates a relative binding affinity for the progesterone receptor (PR) of 125% relative to promegestone (compared to 50% for progesterone itself and 65% for megestrol acetate), while exhibiting negligible affinity for the estrogen receptor (0%), minimal glucocorticoid receptor affinity (6%), and no mineralocorticoid receptor binding [3][4].

NOMAC was categorized by Sitruk-Ware (2004) as a "fourth-generation progestin" alongside dienogest, drospirenone, and trimegestone, reflecting the trend toward progestogens designed for improved receptor selectivity and closer approximation to the physiological effects of progesterone [5]. Multiple clinical guidelines, including those from the International Menopause Society, have recognized the potential advantages of 19-norprogesterone derivatives like NOMAC in menopausal hormone therapy, particularly regarding metabolic neutrality and breast tissue effects [6][7].

Medical / Chemical Identity

Generic Name: Nomegestrol acetate (NOMAC)

Chemical Name: 17alpha-Acetoxy-6-methyl-19-norpregna-4,6-diene-3,20-dione

Molecular Formula: C23H30O4

Molecular Weight: 370.489 g/mol

CAS Number: 58652-20-3

UNII: 83J78V5W05

Drug Class: Progestogen (19-norprogesterone derivative)

ATC Code: G03DB04

First Introduction: 1986 (Europe, for HRT and gynecological disorders)

Brand Names by Country/Region:

Manufacturer: Theramex Ireland Limited (current marketing authorization holder for EU products). Originally developed by Theramex Laboratories (Monaco).

Mechanism of Action

The Basics

NOMAC works by binding to progesterone receptors throughout your body, with a particularly strong effect on the uterine lining. Think of it as a highly targeted key that fits the progesterone lock very precisely, while largely ignoring other hormone locks nearby. This selectivity is the core of its clinical appeal.

In the uterus, NOMAC transforms the lining from a growth phase (driven by estrogen) into a stable, organized state. This is exactly what you need when taking estrogen therapy: it prevents the endometrial overgrowth that can lead to hyperplasia or cancer. NOMAC's affinity for the progesterone receptor is approximately 2.5 times that of natural progesterone, which translates to potent endometrial protection at relatively modest doses [1][8].

NOMAC also has some mild anti-androgenic activity. This means it works against the effects of androgens (male-type hormones), which could theoretically help with symptoms like acne or excess hair growth, though these benefits in menopausal women have not been extensively studied.

One important distinction from micronized progesterone (Prometrium/Utrogestan): NOMAC does not produce allopregnanolone, the calming brain metabolite that gives micronized progesterone its sedative and anxiolytic effects. This means NOMAC is less likely to cause drowsiness, but it also will not provide the sleep-promoting effects that many women appreciate about micronized progesterone [4].

The Science

NOMAC exerts its primary biological effects through high-affinity binding to the nuclear progesterone receptor (PR), functioning as a selective, full agonist. Its binding affinity for the PR is approximately 125% relative to promegestone as the reference ligand, or approximately 2.5 times that of endogenous progesterone [3][4][8].

The receptor selectivity profile of NOMAC is its defining pharmacological characteristic:

• Progesterone receptor (PR): High affinity (Ki approximately 3 nM). Full agonist. Potent endometrial transformation and antigonadotropic activity [3].
• Androgen receptor (AR): Moderate affinity (42% relative to metribolone). Functions as an antagonist, conferring partial antiandrogenic activity estimated at 5-90% of cyproterone acetate potency depending on the assay system [3][4].
• Estrogen receptor (ER): No significant binding (0%) [3].
• Glucocorticoid receptor (GR): Minimal affinity (6%). Clinically insignificant glucocorticoid activity, unlike medroxyprogesterone acetate which has substantial GR binding [3][4].
• Mineralocorticoid receptor (MR): No binding (0%). No antimineralocorticoid effects, distinguishing it from progesterone (which has MR activity) and drospirenone (which has potent antimineralocorticoid effects) [3].

At the endometrial level, NOMAC induces secretory transformation and opposes estrogen-driven proliferation through PR-mediated mechanisms including downregulation of estrogen receptors, induction of local estradiol-inactivating enzymes (17beta-HSD), and stromal decidualization [1][4].

In breast tissue, NOMAC demonstrates several potentially favorable properties: it does not stimulate proliferation of normal or cancerous breast cells in vitro, does not activate the PGRMC1-mediated proliferative pathway (in contrast to some synthetic progestins), and reduces the proliferative effects of estradiol when co-administered in cell culture models. Additionally, NOMAC inhibits steroid sulfatase and stimulates estrogen sulfotransferase activity in breast cells, which may reduce local estrogen concentrations in breast tissue [9][10]. These in vitro findings are consistent with the 19-norprogesterone class profile but have not been confirmed by large-scale clinical outcome studies specific to breast cancer incidence.

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

When you take NOMAC as a tablet, it is absorbed relatively well from your digestive system. About 63% of the dose reaches your bloodstream in active form, which is quite good for an oral progestogen and substantially higher than micronized progesterone (around 15-20%) or medroxyprogesterone acetate (1-10%) [1][4].

One of NOMAC's most distinctive features is its long half-life. It takes approximately 50 hours (roughly two days) for half the drug to clear your system, though this can range from 30 to 80 hours depending on the individual. This is much longer than micronized progesterone (which clears within hours) and means that NOMAC provides more stable blood levels with once-daily dosing. It also means that if you miss a dose, there is more of a buffer before levels drop significantly [1][4].

NOMAC binds primarily to albumin in the blood (97.5-98% protein binding) and does not bind to sex hormone-binding globulin (SHBG) or corticosteroid-binding globulin (CBG). This is worth noting because some progestins affect SHBG levels, which can in turn influence how much free estrogen and testosterone circulate in your body. NOMAC's lack of SHBG binding means it is less likely to alter these dynamics [4].

The liver breaks down NOMAC through a process primarily involving the CYP3A4 enzyme system. This means that medications which affect CYP3A4 activity (such as rifampicin, which speeds it up, or ketoconazole, which slows it down) can change how NOMAC works in your body. The metabolites produced are essentially inactive [4].

The Science

Absorption: NOMAC demonstrates rapid oral absorption, reaching peak serum concentrations within approximately 2-4 hours of administration. Absolute oral bioavailability is 63%, substantially higher than micronized progesterone (~15-20%) or MPA (~1-10%). This superior bioavailability reflects the structural modifications that resist extensive first-pass hepatic metabolism [1][4].

Distribution: Protein binding is 97.5-98%, exclusively to albumin. NOMAC shows no affinity for SHBG or CBG, which differentiates it from levonorgestrel and norethindrone (which bind SHBG) and from progesterone (which binds CBG) [4].

Metabolism: Hepatic metabolism occurs primarily via hydroxylation mediated by CYP3A4, CYP3A3, and CYP2A6. Six main metabolites have been identified, all with no or minimal progestogenic activity. Unlike micronized progesterone, NOMAC does not undergo 5alpha-reduction to neurosteroid metabolites such as allopregnanolone [4].

Elimination: The elimination half-life is approximately 50 hours (range 30-80 hours), among the longest of clinically used progestogens. Steady-state concentrations are achieved after approximately 5 days of repeated administration. Excretion is via both urine and feces [4].

Naemis (HRT) Pharmacokinetics at Steady-State:

The co-administration of estradiol and NOMAC in the Naemis formulation increases the Cmax of estradiol by approximately 25% and NOMAC by approximately 36% compared to separate administration [8].

Understanding how your body absorbs and metabolizes hormones is one thing. Tracking your actual protocol — doses, timing, and route — gives you the data to have more productive conversations with your prescriber. Doserly lets you log every dose with route-specific detail, building a clear record of your hormone protocol over time.

Whether you're on patches, gels, oral tablets, or a combination, the app tracks your schedule and flags when doses are due. When your provider asks how your protocol has been going, you'll have a precise answer instead of a best guess.

Research & Clinical Evidence

The Basics

NOMAC has been studied in clinical practice for several decades, primarily in European research settings. While it does not have the massive randomized controlled trial data that characterizes medications like medroxyprogesterone acetate (studied in the WHI) or micronized progesterone (studied in multiple large observational studies), there is a meaningful body of evidence informing its clinical use.

The evidence broadly suggests that NOMAC is an effective progestogen for endometrial protection, with a metabolic safety profile that compares favorably to older synthetic progestins. Research has consistently found that NOMAC does not negatively affect cholesterol levels, blood sugar regulation, blood clotting parameters, or body weight when combined with estradiol in HRT [1][11].

One area of particular interest is breast tissue effects. Laboratory studies have shown that NOMAC, unlike some other synthetic progestins, does not stimulate the growth of breast cells. In fact, it appears to reduce the proliferative effect of estrogen on breast tissue in test-tube studies [9][10]. While these findings are encouraging, they have not yet been confirmed by large population-level studies examining actual breast cancer rates in NOMAC users compared to users of other progestogens.

The Science

Cardiovascular Risk Factors: A double-blind randomized study by Pélissier et al. (1995) compared two oral estradiol-NOMAC combinations (1 mg E2/2.5 mg NOMAC and 1.5 mg E2/3.75 mg NOMAC) against placebo in 57 nonhysterectomized naturally menopausal women over three treatment cycles. Both active treatments significantly reduced total cholesterol, LDL cholesterol, and lipoprotein(a). The higher-dose combination additionally increased apolipoprotein A1. No significant changes were observed in blood pressure, glucose, HDL cholesterol, triglycerides, antithrombin III, fibrinogen, plasminogen, prothrombin fragment 1+2, protein C, or total and free protein S [11].

Bone Metabolism: Trémollières et al. (2006) conducted a double-blind, randomized, multicenter study in 176 postmenopausal women (1-10 years post-menopause) comparing placebo, 1.5 mg E2 alone, and 1.5 mg E2/3.75 mg NOMAC (Naemis) over 12 weeks. Four biochemical bone turnover markers decreased in the E2/NOMAC group, while only three decreased in the E2-alone group. Notably, deoxypyridinoline (a bone resorption marker) decreased in the E2/NOMAC group but increased slightly in the E2-alone group (p < 0.001), suggesting that NOMAC may enhance the skeletal effects of estradiol [12].

Hemostatic Profile: In vitro data and the Pélissier cardiovascular study demonstrate that NOMAC preserves the beneficial hemostatic effects of estrogen without introducing prothrombotic changes. This is consistent with its lack of glucocorticoid and androgenic receptor activity, which are pathways through which some progestins adversely affect coagulation [1][11].

Breast Tissue Effects: Multiple in vitro studies have demonstrated that NOMAC does not stimulate proliferation of normal or cancerous breast cells (MCF-7, T47-D cell lines). Shields-Botella et al. (2005) showed that NOMAC inhibits steroid sulfatase (reducing conversion of estrone sulfate to estrone) and stimulates estrogen sulfotransferase (promoting inactivation of estrone to estrone sulfate) in breast cancer cells [9]. Neubauer et al. (2013) demonstrated that NOMAC, like natural progesterone, does not stimulate breast cell proliferation through the PGRMC1 pathway, in contrast to some other synthetic progestins [10]. Del Pup et al. (2014) concluded that the endocrine and metabolic profile of NOMAC/E2 formulations should lead to lesser breast tissue stimulation compared to older progestin-containing combinations [13].

Menopausal Symptom Relief: The Naemis SPC confirms that both the estradiol and NOMAC/estradiol treatment phases significantly reduce menopausal complaints in clinical trials. The sequential regimen (estradiol days 1-10, estradiol + NOMAC days 11-24, 4-day break) produces predictable withdrawal bleeding and effective symptom control [8].

Evidence & Effectiveness Matrix

The following matrix uses the 20 HRT symptom/outcome categories. NOMAC is scored only where sufficient evidence exists. Evidence Strength reflects the quality and quantity of clinical research. Reported Effectiveness reflects community-reported outcomes where available.

Categories not scored (insufficient evidence for NOMAC specifically): Anxiety & Stress Response, Cognitive Function, Genitourinary Health (GSM), Body Composition & Weight, Joint & Musculoskeletal Health, Energy & Fatigue, Headache & Migraine, Menstrual & Reproductive, Other Physical Symptoms.

Benefits & Therapeutic Effects

The Basics

The primary benefit of NOMAC in the HRT setting is its ability to protect your uterine lining while you take estrogen, doing so with minimal metabolic side effects. Unlike some older progestins that can partially undo the beneficial effects of estrogen on cholesterol or blood sugar, NOMAC appears to leave these pathways largely undisturbed [1][11].

Clinical studies have shown that the combination of estradiol and NOMAC effectively relieves menopausal symptoms, including hot flashes, night sweats, and vaginal discomfort. The symptom relief comes primarily from the estradiol component, while NOMAC provides the necessary endometrial protection that allows you to take estrogen safely with an intact uterus [8].

Beyond endometrial protection, NOMAC may offer some additional benefits. Its mild anti-androgenic activity could help with androgen-related symptoms that some women experience during and after menopause, though this has not been specifically studied in an HRT population. Research also suggests that NOMAC, when combined with estradiol, may enhance the bone-protective effects of estrogen beyond what estrogen achieves alone [12].

Perhaps most notably, NOMAC's metabolic neutrality means it is less likely to contribute to the weight gain, bloating, or mood disturbances that some women experience with other progestogens. Its lack of glucocorticoid receptor activity is a meaningful advantage over medroxyprogesterone acetate in this regard [1][4].

The Science

Endometrial Protection: NOMAC demonstrates potent secretory transformation of estrogen-primed endometrium, with a PR affinity 2.5 times that of progesterone. The Naemis SPC confirms that the addition of NOMAC greatly reduces the estrogen-induced risk of endometrial hyperplasia in postmenopausal women [8].

Lipid Profile: The Pélissier et al. (1995) RCT demonstrated that E2/NOMAC combinations significantly reduced total cholesterol, LDL cholesterol, and lipoprotein(a) without adversely affecting HDL cholesterol, triglycerides, or other measured lipid parameters. This neutral-to-favorable lipid effect is consistent with NOMAC's lack of androgenic activity [11].

Bone Health: The Trémollières et al. (2006) RCT showed that E2/NOMAC combination reduced all four measured bone turnover markers (bone alkaline phosphatase, osteocalcin, urinary type-I collagen peptides, and deoxypyridinoline), while E2 alone reduced only three. The additional reduction in deoxypyridinoline (a bone resorption marker) in the combination group suggests a synergistic skeletal effect [12].

Hemostatic Neutrality: Available clinical evidence demonstrates that NOMAC does not adversely affect antithrombin III, fibrinogen, plasminogen, prothrombin fragment 1+2, protein C, or total and free protein S when combined with oral estradiol in HRT [11].

Breast Tissue Effects: In vitro evidence consistently demonstrates that NOMAC does not stimulate breast cell proliferation and may actively reduce estrogen-mediated proliferative effects through inhibition of steroid sulfatase and stimulation of estrogen sulfotransferase [9][10][13].

Risks, Side Effects & Safety

The Basics

Like all hormone medications, NOMAC carries potential risks and side effects. The good news is that NOMAC's side effect profile is generally considered mild and its metabolic impact is minimal compared to older progestins.

Common side effects that have been reported include menstrual irregularities (including changes in bleeding patterns, spotting, or periods becoming lighter or absent), headache, nausea, breast tenderness, and in some users, acne. Body weight is generally unchanged, though individual experiences vary [1][2].

A specific safety concern: In France, the national medicines agency (ANSM) has flagged an association between long-term use of NOMAC (as Lutenyl) and the development of meningiomas, which are usually benign brain tumors. Cases of spontaneous meningioma regression after NOMAC discontinuation have been reported [14][15]. While the absolute risk appears to be very low, this association has prompted regulatory scrutiny and is something to discuss with your prescriber, particularly if you are considering long-term use.

Regarding the risks associated with HRT more broadly (blood clots, stroke, breast cancer), it is important to understand that the specific progestogen used matters. NOMAC's profile differs from the medroxyprogesterone acetate (MPA) that was studied in the WHI trial in several important ways: NOMAC has no glucocorticoid activity (MPA has significant GR binding), no androgenic activity (MPA has weak androgenic effects), and has shown favorable breast tissue effects in laboratory studies (whereas MPA has been associated with increased breast cell proliferation).

The Science

Common Side Effects (from clinical data and product information):

• Menstrual irregularities: bleeding pattern changes are the most frequently reported side effect. With the Naemis sequential regimen, predictable withdrawal bleeding typically occurs during the 4-day treatment-free interval [8].
• Headache, nausea, breast tenderness: reported at similar rates to other progestogens.
• Acne: reported in contraceptive studies (Zoely, 15-20% of users), though this may partly reflect the lower estrogen dose in contraceptive formulations [2].
• Body weight: clinical studies consistently show neutral effect on body weight [1].

Meningioma Risk:
Reports from French pharmacovigilance have identified an association between prolonged use of nomegestrol acetate (Lutenyl) and the development of intracranial meningiomas. Case reports have described spontaneous regression of meningiomas following NOMAC discontinuation [14][15]. The ANSM issued safety communications regarding this risk. The absolute incidence remains very low, and the mechanism is hypothesized to involve progesterone receptor expression in meningeal tissue. This risk appears to be dose- and duration-dependent.

Serious Risks in HRT Context (General Progestogen Considerations):

1. Venous thromboembolism (VTE): No specific VTE outcome data exists for NOMAC in menopausal HRT. Contraceptive data from the NOMAC/E2 formulation (Zoely) from a real-world study of over 90,000 users demonstrated no increased VTE risk compared to other combined oral contraceptives [16]. However, oral HRT in general carries a higher VTE risk than transdermal routes, and this applies regardless of the progestogen used.
2. Breast cancer: No large-scale epidemiological study has specifically examined breast cancer incidence with NOMAC-containing HRT. In vitro data is consistently favorable: NOMAC does not stimulate breast cell proliferation and may reduce estrogen-mediated proliferative effects [9][10][13]. However, extrapolating in vitro findings to clinical cancer risk requires caution. The E3N French cohort study, which examined breast cancer risk by progestogen type, did not specifically analyze NOMAC as a separate category.
3. Endometrial cancer: NOMAC provides potent endometrial protection when combined with estrogen, reducing the risk of estrogen-induced endometrial hyperplasia. This is its primary HRT indication [8].
4. Cardiovascular risk: No large-scale cardiovascular outcome studies specific to NOMAC. Available evidence demonstrates neutral effects on lipids, blood pressure, and hemostatic parameters [11].

Contraindications (per Naemis SPC):

• Known or suspected pregnancy
• Active or history of venous thromboembolism
• Active or recent arterial thromboembolic disease
• Known or suspected breast cancer or estrogen-dependent malignancy
• Undiagnosed vaginal bleeding
• Untreated endometrial hyperplasia
• Active liver disease or history of liver disease with abnormal function tests
• Known or suspected meningioma (specific to NOMAC)
• Hypersensitivity to NOMAC, estradiol, or excipients

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you're experiencing breakthrough bleeding, headaches, breast tenderness, or any other change, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also checks for interactions between your HRT and any other medications or supplements you're taking.

Dosing & Treatment Protocols

The Basics

NOMAC dosing in HRT depends on whether you are using the combination product (Naemis) or a standalone tablet (Lutenyl) alongside separate estrogen.

Naemis (combination) regimen:

• Days 1-10: One pink tablet daily (1.5 mg estradiol only)
• Days 11-24: One white tablet daily (1.5 mg estradiol + 3.75 mg NOMAC)
• Days 25-28: Treatment-free interval (4 days)
• This cycle repeats continuously

This is a cyclic sequential regimen, meaning you take estrogen throughout but add the progestogen for only part of the cycle. This pattern mimics the natural menstrual cycle and typically produces a withdrawal bleed during the treatment-free interval [8].

Standalone Lutenyl regimen:
When prescribed independently (usually alongside separate estrogen therapy), NOMAC is typically dosed at 3.75 mg or 5 mg daily for 12-14 days of each cycle. The exact schedule depends on the estrogen formulation being used and your prescriber's preference.

Starting HRT: If you have never taken HRT before, the Naemis combination can be started on any day. If switching from another continuous combined HRT, you can also start on any day. If switching from a sequential regimen, start at the beginning of the next treatment cycle [8].

The Science

Standard Naemis HRT Protocol:

Standalone NOMAC for Endometrial Protection:

Dose Rationale: The 3.75 mg dose in Naemis provides potent endometrial protection while maintaining metabolic neutrality. At this dose, NOMAC effectively suppresses gonadotropin activity and provides complete secretory transformation of the endometrium [1][8].

Titration: NOMAC dosing in HRT is generally not titrated. The established dose (3.75 mg in Naemis) has been demonstrated to provide adequate endometrial protection. Dose adjustment is typically limited to switching between formulations or regimens (e.g., from sequential to continuous) rather than changing the NOMAC dose itself.

Note: All HRT dosing decisions should be made in partnership with a qualified healthcare provider. The doses described here represent established clinical protocols and are not recommendations for self-treatment.

Getting the dosing right often takes time and fine-tuning with your provider. Keeping an accurate record of what you're actually taking — doses, timing, and any adjustments — makes that process smoother. Doserly tracks your HRT doses alongside everything else in your health stack, so your full protocol is always in one place.

Never wonder whether you took your morning dose or when you last changed your patch. The app logs every dose with a timestamp and sends reminders when your next one is due, helping you maintain the consistency that makes hormone therapy most effective.

What to Expect (Timeline)

• Days 1-7: Initial adjustment period. Possible mild nausea, headache, or breast tenderness. These are typically transient. If starting on the Naemis estradiol-only phase, you are receiving estrogen without the progestogen component initially.
• Weeks 2-4: Early symptom response typically begins. Hot flashes and night sweats may start improving (driven by the estradiol component). When NOMAC is added on day 11 (in the Naemis regimen), some women notice breast tenderness or mood changes during the combined phase.
• Months 1-3: Vasomotor symptoms typically improve significantly. Bleeding patterns begin to stabilize. Withdrawal bleeding during the 4-day treatment-free interval should become more predictable. Side effects that appeared initially often settle during this period.
• Months 3-6: Full therapeutic effect for most symptoms. Bone density stabilization begins. Vaginal and urogenital tissues begin to improve (though GSM may require additional local estrogen therapy). Mood and sleep patterns typically stabilize.
• Ongoing maintenance: Annual review with prescriber to reassess symptom control, side effects, and continued appropriateness of therapy. Dose and regimen reassessment. Continued monitoring per guidelines.

Individual response varies considerably. Some women notice improvement within the first week, while others may need 2-3 months of consistent use before the full benefit becomes apparent. Dose adjustment and formulation changes should be discussed with your prescriber rather than managed independently.

Timing Hypothesis & Window of Opportunity

The timing hypothesis proposes that HRT initiated within 10 years of menopause onset or before age 60 has a more favorable risk-benefit profile than HRT started later in life. This applies to all systemic HRT, including NOMAC-containing regimens.

Supporting evidence comes from several landmark studies. The WHI age subgroup analyses demonstrated that women who initiated HRT between ages 50-59 had a more favorable cardiovascular risk profile than those starting after age 60 [17]. The KEEPS trial (Kronos Early Estrogen Prevention Study) and ELITE trial (Early vs Late Intervention Trial with Estradiol) further supported the concept that early initiation may be cardioprotective, while late initiation may increase cardiovascular risk [18][19].

For NOMAC specifically, no timing-specific data exists, as NOMAC was not included in any of these landmark trials (it is not available in North America where these studies were conducted). The timing hypothesis should be applied based on general HRT principles rather than NOMAC-specific evidence.

It is important to present the timing hypothesis as evolving evidence rather than settled science. No randomized controlled trial has been specifically designed and powered to test the timing hypothesis definitively. The clinical relevance lies in informing the shared decision-making conversation between patient and provider about when to initiate HRT.

Interactions & Compatibility

Drug-Drug Interactions:

• CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's Wort): These medications accelerate NOMAC metabolism and may reduce its effectiveness. Dose adjustment or alternative progestogen may be necessary [2][4].
• CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, grapefruit juice): These may increase NOMAC blood levels, potentially intensifying side effects [2].
• Thyroid medications: Estrogen (the co-administered component) increases thyroid-binding globulin, which may require levothyroxine dose adjustment.
• Anticoagulants (warfarin): NOMAC may interact with warfarin and affect INR. Monitoring is recommended.
• Lamotrigine: Estrogen reduces lamotrigine levels significantly; monitor and adjust doses.

Supplement Interactions:

• St. John's Wort: CYP3A4 inducer; may reduce NOMAC effectiveness. Avoid concurrent use.
• Calcium and Vitamin D: No interaction; recommended for bone health alongside HRT.

Lifestyle Factors:

• Smoking: Increases cardiovascular and VTE risk with any oral HRT. This risk is amplified with oral formulations. Smoking cessation is strongly recommended.
• Alcohol: Modest interaction with liver metabolism. Moderate consumption generally acceptable.
• Grapefruit: CYP3A4 inhibitor; may modestly increase NOMAC levels.

Internal Cross-Links:

• Micronized Progesterone (Prometrium) for comparison of progestogen profiles
• Medroxyprogesterone Acetate (Provera) for WHI-studied progestin comparison
• Drospirenone for another fourth-generation progestin
• Dydrogesterone (Duphaston) for another selective progestogen
• Norethindrone Acetate for a 19-nortestosterone-derived progestin comparison
• 17B-Estradiol for the estrogen component used in Naemis

Decision-Making Framework

Choosing a progestogen for HRT is a shared decision between you and your healthcare provider. Several factors may influence whether NOMAC is the right choice for your situation.

NOMAC may be a good fit if:

• You are in a country where it is available (primarily Europe, Latin America, parts of Asia)
• You prefer a progestogen with minimal metabolic side effects
• You have experienced androgenic side effects (acne, oily skin) with other progestins
• You want a progestogen that does not cause drowsiness (unlike micronized progesterone)
• You are concerned about the breast tissue effects associated with some older progestins

NOMAC may not be the best choice if:

• You live in the United States or Canada (not available)
• You have a history of meningioma or are at elevated risk
• You value the sleep-promoting effects of micronized progesterone (NOMAC does not produce allopregnanolone)
• Your provider is unfamiliar with NOMAC (given its limited availability outside certain markets)

Questions to discuss with your provider:

• "How does NOMAC compare to micronized progesterone for endometrial protection?"
• "Is NOMAC appropriate given my specific risk factors?"
• "What monitoring should I expect on NOMAC-containing HRT?"
• "Are there any drug interactions I should be aware of with my current medications?"

Finding a menopause specialist: If your provider is unfamiliar with NOMAC, consider consulting a menopause specialist. In Europe, gynecologists and menopause clinic physicians are typically most familiar with this medication. In the UK, NOMAC (as Zoely) is available but primarily for contraception; the Naemis HRT formulation availability varies.

Administration & Practical Guide

Oral Tablets (Naemis):

• Take one tablet daily at approximately the same time each day
• Tablets can be taken with or without food
• Swallow whole with water
• Follow the sequence: pink tablets (days 1-10), white tablets (days 11-24), then 4-day break
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue as normal. Do not take two doses at once.

Oral Tablets (Lutenyl, standalone):

• Take at the time of day recommended by your prescriber
• Follow the schedule prescribed (typically 12-14 days per cycle)
• Coordinate with your estrogen therapy schedule as directed

Storage: Store at room temperature. Keep out of reach of children. Protect from moisture and light.

Practical notes:

• The long half-life (~50 hours) means that occasional missed doses are less likely to cause breakthrough bleeding or loss of endometrial protection than would be the case with shorter-acting progestogens
• If you experience drowsiness (uncommon with NOMAC, but possible), bedtime dosing may be preferred
• Track your cycle phases carefully, especially with the Naemis sequential regimen, to ensure correct tablet color/sequence

Monitoring & Lab Work

Pre-HRT baseline tests:

• Hormone levels (FSH, estradiol) if diagnosis needs confirmation
• Mammogram (per national screening guidelines)
• Pelvic examination and Pap smear (as per guidelines)
• Blood pressure
• Lipid panel
• Liver function tests (particularly important for oral HRT)
• Bone density (DEXA) if risk factors for osteoporosis present
• Body weight and BMI

Initial follow-up (4-12 weeks):

• Symptom assessment: has NOMAC/estradiol relieved menopausal symptoms?
• Side effect evaluation: bleeding patterns, headache, breast tenderness, mood changes
• Blood pressure check

Ongoing monitoring:

• Mammography: per national guidelines (typically annually or biennially depending on country)
• DEXA scan: baseline and follow-up schedule based on risk profile
• Lipid panel: annually or per cardiovascular risk profile
• Liver function: periodically for oral HRT users
• Endometrial assessment: transvaginal ultrasound if abnormal or unexpected bleeding occurs
• Blood pressure: regular monitoring at each visit
• Annual review: comprehensive reassessment of symptom control, side effects, risk factors, and continued appropriateness of therapy

Complementary Approaches & Lifestyle

Evidence-based complementary strategies that can support HRT outcomes:

Supplements:

• Vitamin D: supports bone health and may have additional benefits for mood and immune function. Most guidelines recommend 600-1000 IU daily, with higher doses for those with documented deficiency.
• Calcium: 1000-1200 mg daily from diet and supplements combined for bone health.
• Omega-3 fatty acids: may support cardiovascular health and reduce inflammation.
• Magnesium: may help with sleep quality and muscle relaxation.

Exercise:

• Weight-bearing exercise for bone health (walking, jogging, dancing, stair climbing)
• Resistance training for body composition and metabolic health
• Cardiovascular exercise for heart health
• Balance training for fall prevention (particularly important for bone health)

Diet:

• Mediterranean diet pattern: associated with cardiovascular protection and reduced inflammation
• Phytoestrogen-rich foods (soy, flaxseed): modest evidence for some menopausal symptom relief
• Calcium-rich foods (dairy, fortified alternatives, leafy greens)
• Limiting alcohol and caffeine: both can worsen hot flashes and sleep disruption

Sleep hygiene: Temperature management in the bedroom, consistent sleep schedule, limiting screen time before bed. If vasomotor symptoms disrupt sleep, optimizing HRT timing and dosing with your provider may help.

Stress management: Mind-body practices such as yoga, meditation, and deep breathing can complement HRT for overall wellbeing.

Cross-references to Doserly supplement guides:

• Vitamin D
• Calcium
• Magnesium
• Omega-3

Stopping HRT / Discontinuation

When to consider stopping:

• Duration-based review: most guidelines recommend reassessing the need for HRT every 1-2 years, though there is no absolute maximum duration
• Changing risk profile: development of contraindications (e.g., breast cancer diagnosis, VTE event, meningioma diagnosis)
• Resolution of symptoms: some women find that menopausal symptoms resolve after several years of treatment
• Patient preference

Tapering strategies:

• Gradual dose reduction over weeks to months is generally preferred over abrupt cessation
• Options include reducing estrogen dose first while maintaining progestogen protection, then tapering both
• Switching from systemic to local (vaginal) estrogen for persistent GSM symptoms
• The long half-life of NOMAC (~50 hours) means that its effects taper more gradually than shorter-acting progestogens

Symptom recurrence:

• An estimated 50% of women experience some symptom return after stopping HRT
• Symptom severity upon recurrence is typically similar to pre-treatment levels, not worse
• Recurrence can occur weeks to months after discontinuation

Monitoring during discontinuation:

• Symptom diary to track any return of vasomotor or other menopausal symptoms
• Bone density follow-up (bone loss may accelerate after HRT cessation)
• Cardiovascular risk reassessment

Special consideration for NOMAC: If discontinuing NOMAC-containing HRT specifically because of the meningioma association, imaging follow-up may be appropriate as cases of meningioma regression after NOMAC cessation have been reported [14][15].

Special Populations & Situations

Breast Cancer Survivors

Systemic HRT, including NOMAC-containing regimens, is generally contraindicated in women with a history of breast cancer. While NOMAC's in vitro profile regarding breast tissue is favorable, no clinical data exists to support its use in breast cancer survivors. Non-hormonal alternatives and vaginal estrogen (for GSM) should be discussed with an oncologist.

Premature Ovarian Insufficiency (POI)

Women with POI require hormone replacement until at least the typical age of menopause (around 51). NOMAC-containing HRT could be appropriate for endometrial protection in these women where available. The long half-life may offer practical advantages for younger women who may have less regular dosing habits.

Surgical Menopause / Oophorectomy

Women who have had both ovaries removed experience abrupt hormone loss. In hysterectomized women, a progestogen is not required. In those with an intact uterus who have had oophorectomy, NOMAC could serve as the progestogen component of combined HRT.

History of VTE

NOMAC-containing oral HRT may not be the best choice for women with a VTE history. While NOMAC itself does not appear to worsen hemostatic parameters, the oral route of estrogen administration carries higher VTE risk than transdermal. Women with VTE history should discuss transdermal estrogen options with their provider.

Migraine with Aura

Stable estrogen levels are important for migraine management. The sequential Naemis regimen, with its estrogen-only phase followed by combined phase and treatment break, may cause hormonal fluctuations that could trigger migraines. Continuous combined regimens (which may be available with standalone NOMAC + continuous transdermal estrogen) might be preferable.

Meningioma History

NOMAC is specifically contraindicated in women with known or suspected meningioma, given the pharmacovigilance signal from French regulatory data [14][15]. Alternative progestogens should be used.

Regulatory, Insurance & International

Regulatory Status by Jurisdiction:

Why is NOMAC not available in the US?
The FDA rejected the NDA for Zoely (the contraceptive formulation) in 2011. The specific reasons have not been fully disclosed publicly, but the rejection effectively prevented NOMAC from entering the US market in any formulation [2]. This means that NOMAC is not available through US pharmacies, cannot be prescribed by US clinicians through standard channels, and is not covered by US insurance plans.

Cost and Access:

• In France, NOMAC (Lutenyl) and Naemis are reimbursed under the national health insurance system
• In other European countries, coverage varies by national formulary
• Generic nomegestrol acetate tablets are available in some markets
• For women traveling or living abroad who wish to continue NOMAC-containing HRT, maintaining a relationship with a prescriber in a country where NOMAC is available is necessary

Brand Name Cross-Reference:

Frequently Asked Questions

Q: Is nomegestrol acetate the same as micronized progesterone?
No. Micronized progesterone (Prometrium, Utrogestan) is molecularly identical to the progesterone your body produces naturally. Nomegestrol acetate is a synthetic progestogen derived from the 19-norprogesterone structural family. While both bind to the progesterone receptor and provide endometrial protection, they differ in metabolism, half-life, receptor selectivity, and side effect profiles. NOMAC has a much longer half-life (~50 hours vs a few hours) and does not produce the sleep-promoting neurosteroid metabolite allopregnanolone.

Q: Why is NOMAC not available in the United States?
The FDA rejected the NDA for Zoely (the NOMAC/estradiol contraceptive) in 2011. The specific grounds for rejection have not been fully detailed publicly. This means NOMAC is not marketed in the US in any formulation. It remains widely available in Europe, Latin America, and parts of Asia and Oceania.

Q: Does NOMAC cause weight gain?
Clinical studies consistently show that NOMAC has a neutral effect on body weight. Unlike some progestogens with glucocorticoid or androgenic activity that may promote fluid retention or metabolic changes, NOMAC's receptor selectivity means it is less likely to contribute to weight gain.

Q: Can I take NOMAC if I have a history of blood clots?
NOMAC itself does not appear to adversely affect hemostatic parameters. However, any oral HRT carries VTE risk primarily from the oral estrogen component's first-pass hepatic effects. Women with VTE history should discuss transdermal estrogen options with their provider. The progestogen choice is secondary to the estrogen route in VTE risk management.

Q: Is NOMAC safer for breast tissue than other progestogens?
In vitro studies consistently show that NOMAC does not stimulate breast cell proliferation and may reduce estrogen-mediated proliferative effects. However, no large-scale clinical study has specifically examined breast cancer rates in NOMAC HRT users. While the laboratory data is encouraging, clinical outcome data is needed to confirm any breast safety advantage.

Q: Does NOMAC help with sleep like progesterone does?
No. Unlike micronized progesterone, which is metabolized into allopregnanolone (a GABA-A receptor modulator with sedative properties), NOMAC does not produce neurosteroid metabolites. This means NOMAC will not provide the drowsiness or sleep-promoting effects associated with micronized progesterone. For some women, this is an advantage (no daytime drowsiness); for others who rely on progesterone for sleep support, it may be a disadvantage.

Q: What is the meningioma risk with NOMAC?
French pharmacovigilance has identified an association between prolonged NOMAC use and the development of meningiomas (usually benign brain tumors). The absolute risk is very low, and cases of spontaneous regression after NOMAC discontinuation have been reported. This risk is monitored by European regulatory authorities and should be discussed with your prescriber, particularly for long-term use.

Q: How does the Naemis regimen compare to continuous combined HRT?
Naemis uses a cyclic sequential approach: estrogen alone for 10 days, then estrogen plus NOMAC for 14 days, with a 4-day break. This typically produces a predictable withdrawal bleed. Continuous combined HRT (estrogen plus progestogen every day without a break) eventually aims for no bleeding. The choice between sequential and continuous regimens depends on individual preference, how far past menopause you are, and your provider's recommendation.

Q: Can I switch to NOMAC from another progestogen?
Yes, switching between progestogens is common in HRT. Your provider can guide the transition. If switching from continuous combined HRT to Naemis, you can generally start on any day. If switching from another sequential regimen, starting at the beginning of the next cycle is typically recommended.

Q: Is NOMAC appropriate during perimenopause?
NOMAC can be used during perimenopause, though the Naemis combination is specifically indicated for postmenopausal women. During perimenopause, standalone NOMAC (Lutenyl) may be prescribed for menstrual irregularities or as progestogen supplementation. Discuss the most appropriate approach with your provider.

Q: Does NOMAC interact with antidepressants?
There are no major known direct interactions between NOMAC and SSRIs, SNRIs, or other common antidepressants. However, estrogen (the co-administered component) may affect the metabolism of certain medications. Always inform your prescriber of all medications you are taking.

Myth vs. Fact

Myth: "All synthetic progestogens are the same and carry the same risks."
Fact: Progestogens differ substantially in their receptor binding profiles and biological effects. NOMAC is a 19-norprogesterone derivative with high selectivity for the progesterone receptor and essentially no androgenic, estrogenic, or glucocorticoid activity. This differs markedly from medroxyprogesterone acetate (which has significant glucocorticoid activity), norethindrone (which has androgenic activity), and levonorgestrel (which has strong androgenic effects). The WHI findings regarding MPA cannot be directly applied to all progestogens [1][3][4][5].

Myth: "NOMAC causes breast cancer like other HRT progestogens."
Fact: No epidemiological study has specifically demonstrated an increased breast cancer risk with NOMAC. In vitro evidence consistently shows that NOMAC does not stimulate breast cell proliferation and may reduce estrogen-mediated proliferative effects in breast tissue [9][10][13]. However, absence of evidence is not evidence of absence, and long-term population-level breast cancer data specific to NOMAC is needed.

Myth: "If it's not available in the US, it must not be safe."
Fact: NOMAC's absence from the US market reflects a regulatory decision (FDA rejected the NDA in 2011), not a safety determination. NOMAC has been used safely in European clinical practice since 1986 and is approved by the EMA, MHRA, TGA, and numerous other regulatory agencies. Many medications are available in some countries but not others due to commercial, regulatory, or strategic reasons unrelated to safety [2].

Myth: "Natural progesterone is always better than synthetic progestogens."
Fact: Micronized progesterone and synthetic progestogens each have advantages and disadvantages. Micronized progesterone produces sleep-promoting neurosteroid metabolites and has favorable breast tissue data. NOMAC offers superior oral bioavailability (63% vs 15-20%), a much longer half-life providing more stable levels, and does not cause drowsiness. The "best" progestogen depends on individual clinical needs, side effect tolerance, and availability.

Myth: "NOMAC causes brain tumors."
Fact: French pharmacovigilance has identified an association between prolonged NOMAC use and meningiomas (typically benign tumors of the brain's protective membranes). The absolute risk is very low, and cases have shown regression after NOMAC discontinuation [14][15]. This association has led to specific monitoring recommendations but has not resulted in NOMAC being withdrawn from any market. It is appropriate to discuss this risk with your prescriber, particularly for long-term use.

Myth: "HRT should only be taken for 5 years maximum."
Fact: The "5-year rule" is outdated. Current guidelines from the International Menopause Society, the Menopause Society (formerly NAMS), and other organizations recommend individualized duration assessment rather than arbitrary time limits. For many women, the benefits of continued HRT beyond 5 years outweigh the risks, particularly for bone protection, quality of life, and genitourinary health. Duration decisions should be based on ongoing risk-benefit assessment with your healthcare provider.

Myth: "You don't need a progestogen if your periods have stopped."
Fact: If you have an intact uterus, you need progestogen protection whenever you take systemic estrogen, regardless of whether you are still menstruating. Estrogen stimulates endometrial growth, and without progestogen opposition, the risk of endometrial hyperplasia and cancer increases. This applies to all systemic estrogen therapy, including patches, gels, sprays, and oral tablets [8].

Myth: "All HRT increases blood clot risk equally."
Fact: VTE risk with HRT is primarily driven by the estrogen component and its route of administration. Oral estrogen increases VTE risk through first-pass hepatic effects on coagulation factor synthesis. Transdermal estrogen consistently shows no significant VTE risk increase across multiple studies. The choice of progestogen (including NOMAC vs alternatives) appears to be secondary to the estrogen route in determining VTE risk.

Sources & References

Clinical Guidelines:

1. Lello S. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs. 2010;70(5):541-559. doi:10.2165/11532130-000000000-00000. PMID: 20329803.

Pharmacological References:
2. Burke A. Nomegestrol acetate-17beta-estradiol for oral contraception. Patient Prefer Adherence. 2013;7:607-619. doi:10.2147/PPA.S39371. PMC3702550.
3. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3-63. doi:10.1080/13697130500148875. PMID: 16112947.
4. Ruan X, Seeger H, Mueck AO. The pharmacology of nomegestrol acetate. Maturitas. 2012;71(4):345-353. doi:10.1016/j.maturitas.2012.01.007. PMID: 22364709.

Landmark and Comparative Studies:
5. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(13):865-883. PMID: 15493951.
6. Binkowska M, Woron J. Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015;14(2):134-143. doi:10.5114/pm.2015.52154. PMC4498031.
7. Mueck AO, Ruan X, Seeger H, et al. The "newer" progestogens and postmenopausal hormone therapy. Maturitas. 2014;77(2):171-175. PMID: 24333799.

Product Information:
8. Naemis Summary of Product Characteristics (HPRA Ireland). PA0654-014-001.

Breast Tissue Studies:
9. Shields-Botella J, Chetrite G, Meschi S, Pasqualini JR. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J Steroid Biochem Mol Biol. 2005;93(1):1-13. PMID: 15748827.
10. Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development. Climacteric. 2013;16(5):509-513. doi:10.3109/13697137.2013.800038. PMID: 23758160.

Cardiovascular and Metabolic Studies:
11. Pélissier C, Maroni M, Yaneva H, et al. A placebo-controlled study with nomegestrol acetate and estradiol on cardiovascular risk factors. Fertil Steril. 1995;64(4):693-697. PMID: 7589641.

Bone Health Studies:
12. Trémollières FA, Pouillès JM, Ribot C. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover. Maturitas. 2006;53(3):252-259. PMID: 16096169.

Breast Cancer Risk:
13. Del Pup L, Berretta M, Di Francia R, et al. Nomegestrol acetate/estradiol hormonal oral contraceptive and breast cancer risk. Anti-Cancer Drugs. 2014;25(7):745-750. PMID: 24346139.

Meningioma Safety Signal:
14. Passeri T, Champagne PO, Bernat AL, et al. Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients. Acta Neurochir. 2019;161(4):761-765. PMID: 30783806.
15. Champagne PO, Passeri T, Froelich S. Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma. Acta Neurochir. 2019;161(3):589-592. PMID: 30666456.

Real-World Safety Data:
16. Fruzzetti F, Bonassi Machado R, Lete I, et al. A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2. Eur J Obstet Gynecol Reprod Biol X. 2024;21:100283.

Timing Hypothesis:
17. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477.
18. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Ann Intern Med. 2014;161(4):249-260.
19. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med. 2016;374(13):1221-1231.

Related Guides & Cross-Links

Same Category (Progestogens)

• Micronized Progesterone (Prometrium) — Bioidentical progesterone; produces sleep-promoting allopregnanolone; most widely recommended progestogen
• Medroxyprogesterone Acetate (Provera) — Synthetic progestogen studied in WHI; different receptor profile (GR binding)
• Norethindrone Acetate (Aygestin) — 19-nortestosterone derivative with androgenic activity
• Drospirenone — Fourth-generation progestin with antimineralocorticoid activity
• Dydrogesterone (Duphaston) — Retroprogesterone with selective PR binding
• Levonorgestrel (Mirena IUD) — Local progestogen delivery via intrauterine system

Related Treatment Options

• 17B-Estradiol (Bioidentical) — The estrogen component used in Naemis combination
• Estradiol + Progesterone (Bijuva) — Alternative combined E+P product
• Getting Started with HRT — Overview guide for HRT initiation

Complementary Approaches

• Vitamin D — Bone health support
• Calcium — Bone mineral density
• Magnesium — Sleep and muscle relaxation